Javid Moslehi

December 22, 2020

Arthritis drug may treat immunotherapy-related heart complication

By Tom Wilemon
March 12, 2020

Clinical investigation society lauds Vanderbilt scientists

Five faculty members of Vanderbilt University School of Medicine are among 80 physician-scientists who will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. They are:

By Bill Snyder
The study team included, from left, Douglas Johnson, MD, Dan Roden, MD, Javid Moslehi, MD, Joe-Elie Salem, MD, PhD, and Ali Manouchehri, MD.
September 25, 2019

Study identifies targeted therapy’s cardiac risks

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

By Tom Wilemon
February 21, 2019

AHA statement supports vascular cardio-oncology

The American Heart Association (AHA) has issued a scientific statement calling for the integration of cardio-oncology and vascular medicine to provide cancer patients and cancer survivors with optimal cardiovascular care.

By Tom Wilemon
November 15, 2018

Immunotherapies linked to specific heart complications

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

By Tom Wilemon
March 12, 2018

Cancer immunotherapy drugs linked with more serious heart effects

Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy.

By VUMC News and Communications
February 28, 2017

My Southern Health: The ABCDEs of caring for the heart during cancer treatment—and beyond

People who have dealt with cancer may also need to take special care of their hearts. Here’s how.
By VUMC News and Communications
November 3, 2016

Study details rare heart risk of certain cancer therapies

By VUMC News and Communications
October 27, 2016

Emerging field of cardio-oncology seeks better tools

Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism.
By VUMC News and Communications
February 4, 2016

Prostate cancer survivors’ risk of heart disease studied

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression.
By Kathy Whitney
September 24, 2015

Cancer therapies’ impact on heart, kidneys explored

Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys.
By Kathy Whitney
October 2, 2014

Program focuses on heart health of cancer patients

The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States.
By Kathy Whitney